

SUPPLEMENTARY FIGURE 3




Figure S3: Differences in T helper subsets before and after treatment with omalizumab. Percentages of (A) Th1 Effector Memory ($CD3^+CD4^+CCR7^+CD45RA^-CXCR3^+CCR6^-$), (B) Th2 Central Memory ($CD3^+CD4^+CCR7^+CD45RA^-CXCR3^-CCR6^-$), (C) activated CD4 ($CD3^+CD4^+HLA-DR^+CD38^+$), (T cells in peripheral blood of patients before(n=14) and 6 months after(n=24) treatment with omalizumab.